查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1950555

注射用齐拉西酮甲磺酸盐市场按适应症、规格、包装、年龄层和最终用户划分，全球预测，2026-2032年

Ziprasidone Mesylate for Injection Market by Indication, Strength, Packaging, Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，注射用齐拉西酮甲磺酸盐市场价值将达到 13.9 亿美元，到 2026 年将成长至 15.1 亿美元，到 2032 年将达到 26.8 亿美元，年复合成长率为 9.84%。

关键市场统计数据
基准年 2025 13.9亿美元
预计年份：2026年 15.1亿美元
预测年份 2032 26.8亿美元
复合年增长率 (%) 9.84%

本文全面介绍了注射甲磺酸齐拉西酮在急性精神科治疗中的临床作用、操作限制和相关人员的优先事项。

本导言概述了注射甲磺酸齐拉西酮在急性精神疾病治疗中的治疗作用和临床效用，为更深入的操作和策略分析奠定了基础。作为一种肌注抗精神病药物，该製剂可快速控制精神分裂症的急性躁郁症和思觉失调症的急性躁狂发作，当口服给药因患者躁动或依从性风险而不可行或无效时，它便能满足临床需求。临床医生依靠注射来稳定患者病情、快速镇静行为紧急情况，并促进患者及时过渡到长期口服治疗。

临床优先事项、供应链韧性和监管收紧正在重塑全球注射精神药物模式。

注射型精神科治疗领域正经历变革性的转变，其驱动力包括不断发展的临床实践、供应链重组以及监管的加强。临床医师越来越重视起效迅速、安全性高的介入措施，以最大限度地减少对病人的约束需求，并降低急诊就诊量。这种临床趋势提升了注射型抗精神病药物的战略重要性，这类药物具有起效可预测、不利事件可控以及与医院监测通讯协定相容等优点。

2025年美国关税对无菌注射剂供应链的影响：营运与采购评估

美国2025年实施的累积关税对药品供应链产生了广泛影响，尤其对无菌注射疗法影响显着。进口原料药和包装材料的关税增加了依赖国际采购的製造商的成本，促使他们即时采取战术性措施，例如重新谈判供应商合约和短期价格调整。这些措施也加速了企业多元化供应链网路和将关键生产环节迁至更靠近终端市场的策略进程。

详细的細項分析揭示了临床严重程度、最终用户环境、配方强度、包装和年龄组考虑因素如何相互作用，从而决定产品的使用情况。

细分市场分析揭示了临床、采购和製剂变数如何相互作用，共同塑造注射用齐拉西酮甲磺酸盐的需求和使用模式。根据适应症，该产品用于治疗思觉失调症的急性躁动和双相情感障碍的急性躁郁症躁症发作，并根据严重程度进一步分为中度和重度。这些临床阶段会影响剂量选择、监测强度和给药环境偏好。根据最终用户，该产品在医院药房（包括急诊和精神科病房）以及专科诊所（包括日间医院和门诊诊所）均有供应。这些不同的环境有不同的人员配备模式、处方集和储存方式，进而影响订购频率和管瓶配置偏好。

区域分析突显了美洲、欧洲、中东和非洲以及亚太地区在註射剂采购、临床应用和供应稳定性方面的差异。

区域趋势对注射用齐拉西酮甲磺酸盐的可及性、采购惯例和临床应用模式有显着影响。在美洲，成熟的医院系统和一体化的供应链确保了可预测的处方集週期和大规模预算，但集中式的低温运输和无菌製造地也使其容易受到区域供应中断的影响。该地区的临床医生越来越重视药物的快速疗效和可靠的安全性监测，这正在影响医院的用药选择和培训投入。

竞争考察和营运状况分析，重点在于注射剂治疗领域中创新药厂、非专利和无菌契约製造生产商不断变化的角色。

注射用精神科药物市场的竞争格局由成熟的创新药厂、非专利参与企业和专业的无菌契约製造共同构成，它们各自为供应链带来不同的优势。拥有成熟配方的成熟製药公司在临床医生认可度、监管文件和完善的药物监测系统方面保持优势，这些优势有助于其处方笺被纳入医院处方集。同时，非专利生产商和二线参与企业专注于成本竞争力和营运效率，通常在管瓶规格、供应可靠性和快速分销方面竞争。

为製造商、医院采购部门和临床领导者提供切实可行的建议，以加强注射疗法的供应韧性、优化利用率并降低临床风险

製造商、医院采购和临床实践领域的领导者可以采取切实可行的措施，提高注射用齐拉西酮甲磺酸盐的可及性并优化其治疗价值。製造商应优先考虑供应链的透明度和多元化，投资于替代原料药来源以及本地无菌填充和包装能力，以降低贸易政策变化和物流中断的风险。此外，还应加强上市后安全计画和临床医生教育，以解决影响医疗机构采用的剂量差异和心电图监测的注意事项。

结合临床医生访谈、监管审查和供应链分析，采用稳健的混合调查方法，以产生可操作的营运洞察。

本调查方法整合了多方面的证据分析、专家咨询和营运分析，旨在全面了解注射用齐拉西酮甲磺酸盐的市场环境。主要研究内容包括对急诊、精神科病房、日间医院和门诊的临床医生进行结构化访谈，以收集实际用药实践和安全方面的考量。这些临床见解，以及与医院采购负责人和无菌契约製造的讨论，揭示了供应链动态、包装偏好和营运限制。

综合概述临床应用、供应链韧性和策略采购，以指导未来的准入和营运规划

总之，注射使用齐拉西酮甲磺酸盐在急性精神疾病治疗中占有重要地位，因为这类疾病需要快速起效、安全有效且供应可靠。临床需求源自于治疗思觉失调症发作的需要，而口服给药在这些情况下并不适用，因此对给药方案的柔软性、包装选择和监测通讯协定提出了特殊要求。同时，近期关税政策的变化以及全球供应链面临的压力凸显了多元化采购、区域生产能力以及製造商、医院和契约製造之间更紧密合作的必要性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 注射以齐拉西酮甲磺酸盐市场依适应症划分

  • 思觉失调症急性躁动
    • 缓和
    • 严重
  • 双极性情感障碍的急性躁郁症发作
    • 缓和
    • 严重

9. 注射以齐拉西酮甲磺酸盐市场（依浓度划分）

  • 20mg
  • 40mg
  • 60 mg

10. 注射用齐拉西酮甲磺酸盐市场（依包装类型划分）

  • 多剂量管瓶
  • 单剂量管瓶

第十一章 依年龄组别分類的注射用齐拉西酮甲磺酸盐市场

  • 成年患者
  • 老年患者

第十二章 注射用齐拉西酮甲磺酸盐市场（依最终用户划分）

  • 医院药房
    • 急诊室
    • 精神病房
  • 专科诊所
    • 日间医院
    • 门诊部

13. 注射用齐拉西酮甲磺酸盐市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 注射用齐拉西酮甲磺酸盐市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国注射用齐拉西酮甲磺酸盐市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国註射用齐拉西酮甲磺酸盐市场

17. 中国注射用齐拉西酮甲磺酸盐市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Jubilant Generics Limited
  • Lupin Limited
  • Mylan NV
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Cadila
Product Code: MRR-4F7A6D4FD8DA

The Ziprasidone Mesylate for Injection Market was valued at USD 1.39 billion in 2025 and is projected to grow to USD 1.51 billion in 2026, with a CAGR of 9.84%, reaching USD 2.68 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.39 billion
Estimated Year [2026] USD 1.51 billion
Forecast Year [2032] USD 2.68 billion
CAGR (%) 9.84%

Comprehensive introduction to the clinical role operational constraints and stakeholder priorities surrounding injectable ziprasidone mesylate in acute psychiatric care

The introduction outlines the therapeutic role and clinical utility of ziprasidone mesylate for injection within acute psychiatric care settings, setting a foundation for deeper operational and strategic analysis. As an intramuscular antipsychotic used to rapidly manage acute agitation in schizophrenia and acute manic episodes in bipolar disorder, this formulation fills a critical need where oral administration is impractical or ineffective due to patient agitation or risk of noncompliance. Clinicians rely on injectable options to stabilize patients, enable rapid de-escalation of behavioral emergencies, and facilitate timely transitions to longer-term oral regimens.

Beyond clinical use, injectable ziprasidone mesylate presents distinct manufacturing and logistics requirements, including aseptic production, sterility assurance, and packaging considerations that influence distribution and hospital formulary decisions. Regulatory scrutiny around cardiac safety and appropriate monitoring informs clinical protocols and training needs in emergency and psychiatric ward settings. Consequently, stakeholders across pharmacy, clinical leadership, procurement, and manufacturing must coordinate to ensure safe, reliable access while maintaining adherence to evolving safety guidelines and institutional policies.

This report's introductory analysis establishes the clinical rationale, operational constraints, and stakeholder imperatives that frame downstream sections focused on market dynamics, tariff impacts, segmentation, regional variations, competitive behavior, and action-oriented recommendations.

How clinical priorities supply chain resilience and regulatory tightening are jointly reshaping the global injectable psychiatric therapeutics environment

The landscape for injectable psychiatric treatments is undergoing transformative shifts driven by evolving clinical practice, supply chain reconfiguration, and intensified regulatory oversight. Clinicians increasingly prioritize rapid-acting, high-safety-profile interventions that minimize the need for physical restraints and reduce emergency department throughput. This clinical emphasis has elevated the strategic importance of injectable antipsychotics that offer predictable onset, manageable adverse event profiles, and compatibility with hospital monitoring protocols.

Parallel to clinical trends, supply chains are being redesigned to improve resilience against geopolitical shocks and pharmaceutical shortages. Manufacturers and health systems are investing in redundant sourcing, regional contract manufacturing, and inventory optimization to protect access to critical injectables. Regulatory bodies are tightening expectations for post-marketing surveillance and risk mitigation plans, particularly for products with known safety considerations, which requires manufacturers to invest in enhanced pharmacovigilance and clinician education.

Together, these forces are catalyzing shifts in procurement behavior, fostering closer collaboration between manufacturers and providers, and accelerating innovation in packaging, dosing flexibility, and administration protocols. These trends underscore a market environment in which operational agility, robust quality systems, and clinical evidence of safety and rapid efficacy confer competitive advantage.

Assessing the operational and procurement consequences of United States tariff measures introduced in 2025 that disrupted sterile injectable supply chains

Cumulative tariff actions implemented by the United States in 2025 have produced broad implications for the pharmaceutical supply chain, with particular relevance to sterile injectable therapies. Tariffs on imported active pharmaceutical ingredients and packaging components have increased the cost basis for manufacturers that rely on international sourcing, prompting immediate tactical responses including renegotiation of supplier contracts and short-term price adjustments. These measures have also accelerated strategic initiatives to diversify supply networks and relocate critical manufacturing steps closer to end markets.

Hospitals and specialty clinics have felt secondary effects through procurement cycles, with supply officers reassessing long-term purchasing agreements and inventory policies to mitigate exposure to ongoing tariff volatility. In response, manufacturers have prioritized transparency with institutional purchasers, sharing supply risk assessments and collaborating on buffer stock strategies. Regulatory timelines have occasionally been impacted where component substitutions or manufacturing site changes require additional validation, lengthening lead times for certain batches.

Importantly, tariff-driven cost pressures are not uniform across all participants. Firms with vertically integrated manufacturing and established domestic sterile production capacity have been better positioned to absorb incremental costs, whereas pure contract manufacturers dependent on imported raw materials have faced tighter margins. As a result, expect continued emphasis on supply chain mapping, regionalization of production, and contractual safeguards to stabilize access to injectable ziprasidone mesylate amid persistent trade policy uncertainty.

In-depth segmentation analysis revealing how clinical severity end-user setting formulation strength packaging and age group considerations interact to determine product use

Segmentation analysis clarifies how clinical, procurement, and formulation variables intersect to shape demand and usage patterns for injectable ziprasidone mesylate. Based on indication, the product is used for acute agitation in schizophrenia and acute manic episodes in bipolar disorder, each of which is further differentiated by severity into moderate and severe presentations; these clinical gradations influence dosing choices, monitoring intensity, and administration setting preferences. Based on end user, the product serves hospital pharmacy environments including the emergency department and psychiatric ward, as well as specialty clinic contexts that encompass day hospitals and outpatient clinics; these distinct settings have different staffing models, formularies, and storage practices that affect ordering cadence and vial configuration preferences.

Based on strength, the injectable portfolio includes 20 mg, 40 mg, and 60 mg options, enabling clinicians to tailor doses to patient severity and tolerability while facilitating step-down strategies in acute care pathways. Based on packaging, available formats include multi-dose vials and single-dose vials, with multi-dose vials offering inventory efficiencies for higher-volume hospital wards and single-dose vials reducing cross-contamination risk in lower-volume clinics. Based on age group, the product is deployed across adult and geriatric patients, where geriatric use prompts additional safety considerations, dose adjustments, and monitoring for comorbidities.

Taken together, these segmentation lenses reveal that commercial and clinical strategies must be finely tuned to the interplay of indication severity, administration setting, strength availability, packaging choice, and patient age to ensure optimal therapeutic and operational outcomes.

Regional landscape analysis demonstrating how Americas Europe Middle East Africa and Asia-Pacific differ in procurement clinical adoption and supply resilience for injectables

Regional dynamics materially influence access, procurement practices, and clinical adoption patterns for injectable ziprasidone mesylate. In the Americas, established hospital systems and integrated supply chains favor predictable procurement cycles and larger formulary budgets, yet the region also contends with concentrated cold chain and sterile manufacturing hubs that create vulnerability to localized disruptions. Clinicians in this region increasingly demand evidence of rapid efficacy and robust safety monitoring, which shapes hospital adoption and training investments.

In Europe, the Middle East & Africa, variability in public procurement mechanisms, regulatory harmonization, and healthcare infrastructure results in heterogeneous access. Some countries operate centralized tender systems that prioritize cost-effectiveness and long-term supply agreements, while others rely on decentralized procurement that amplifies variability in vial format preference and strength availability. The region's diverse clinical guidelines and differing levels of acute psychiatric service capacity create a complex landscape for manufacturers seeking to align distribution and support services.

In Asia-Pacific, rapid healthcare modernization and investment in emergency and mental health services are expanding demand for acute injectable therapies, but reliance on global API and packaging supply chains makes the region sensitive to tariff shifts and logistical constraints. Local contract manufacturing growth and regional regulatory maturation offer pathways to improve supply resilience and to tailor packaging and dosing options to the needs of high-volume hospital systems and community-based clinics.

Across all regions, stakeholder collaboration, regional manufacturing investments, and tailored clinical support programs are critical to ensuring consistent access and appropriate usage of injectable ziprasidone mesylate.

Competitive and operational company insights highlighting the evolving roles of innovators generics and sterile contract manufacturers in injectable therapeutics

Competitive dynamics in the injectable psychiatric therapeutics space are shaped by legacy innovators, generic entrants, and specialized sterile contract manufacturers, each bringing distinct capabilities to the supply chain. Established pharmaceutical firms with proven formulations retain advantages in clinician familiarity, regulatory dossiers, and established pharmacovigilance systems, which supports hospital formulary inclusion. Meanwhile, generic manufacturers and secondary entrants focus on cost competitiveness and operational efficiencies, often competing on vial formats, supply reliability, and responsive distribution.

Contract manufacturing organizations that specialize in aseptic fill-finish operations play an increasingly pivotal role, enabling brand owners to scale production without the capital burden of expanding sterile manufacturing capacity. These providers also support rapid qualification of alternative packaging and vial sizes to match end-user needs. Strategic partnerships between product owners and large hospital systems or group purchasing organizations are becoming more common, aligning production planning with predictable demand streams and enabling joint investments in safety training and inventory management solutions.

Innovation efforts center on improving dosing flexibility, simplifying administration protocols, and strengthening post-market safety surveillance. Companies that can combine clinical support services, reliable aseptic manufacturing, and transparent supply chain risk communication will be best positioned to meet institutional purchasers' expectations and secure long-term placement in acute care formularies.

Practical recommendations for manufacturers hospital procurement and clinical leaders to strengthen supply resilience optimize utilization and reduce clinical risk for injectable therapies

Leaders across manufacturing, hospital procurement, and clinical practice can take specific, actionable steps to fortify access and optimize the therapeutic value of injectable ziprasidone mesylate. Manufacturers should prioritize supply chain visibility and diversification, investing in alternate API sources and regional aseptic fill-finish capacity to reduce vulnerability to trade policy changes and logistical disruptions. They should also strengthen post-marketing safety programs and clinician education to address dosing nuances and cardiac monitoring considerations that influence institutional adoption.

Hospital and clinic leaders should incorporate scenario-based procurement planning that balances inventory resilience with shelf-life considerations and storage constraints. Procurement teams ought to negotiate contractual clauses that promote supply continuity, such as dual-sourcing agreements and prioritized allocation commitments. Clinicians and pharmacy leaders should collaborate to standardize administration protocols across emergency departments, psychiatric wards, day hospitals, and outpatient clinics, thereby reducing variability in patient handling and improving safety outcomes.

Across the ecosystem, stakeholders should pursue collaborative pilots that test alternative vial formats, dosing algorithms, and remote monitoring tools to minimize adverse events and streamline transitions from acute injectable treatment to oral maintenance therapy. These approaches will reduce clinical risk, improve patient throughput, and strengthen institutional readiness for future supply chain shocks.

Robust mixed-methods research approach combining clinician interviews regulatory review and supply chain analysis to generate actionable operational insights

The research methodology combines a multi-source evidence approach with expert consultation and operational analysis to produce a comprehensive view of the injectable ziprasidone mesylate environment. Primary inputs include structured interviews with clinicians across emergency departments, psychiatric wards, day hospitals, and outpatient clinics to capture real-world administration practices and safety concerns. These clinical insights were complemented by discussions with hospital procurement professionals and sterile contract manufacturers to map supply chain dynamics, packaging preferences, and operational constraints.

Secondary research encompassed regulatory guidance, safety advisories, and peer-reviewed clinical literature to ensure accuracy on indication-specific use, dosing standards, and monitoring recommendations. Supply chain and trade policy analysis integrated customs and tariff announcements, industry reports on sterile manufacturing capacity, and public filings to assess the implications of recent tariff actions. The methodology emphasized triangulation across sources to validate findings and to surface practical strategies that stakeholders can implement.

Limitations include variability in regional procurement practices and the evolving nature of trade policy, which may alter the operational landscape over time. To address this, the methodology incorporated sensitivity checks and sought expert validation to ensure robustness of directional insights and operational recommendations.

Concluding synthesis tying clinical use supply chain resilience and strategic procurement together to guide future access and operational planning

In conclusion, injectable ziprasidone mesylate occupies a critical niche in acute psychiatric care where rapid efficacy, safety management, and supply reliability converge. Clinical demand stems from the need to manage acute agitation in schizophrenia and manic episodes in bipolar disorder when oral routes are not viable, and this creates specific requirements around dosing flexibility, packaging options, and monitoring protocols. Simultaneously, recent tariff developments and global supply chain pressures have highlighted the need for diversified sourcing, regional manufacturing capacity, and closer coordination between manufacturers, hospitals, and contract manufacturers.

Strategic responses that combine enhanced pharmacovigilance, targeted clinician education, and investment in sterile manufacturing resilience will help secure access and maintain high standards of patient care. Procurement strategies that emphasize contractual protections, inventory optimization, and cross-stakeholder pilots can mitigate short-term disruptions while supporting longer-term system improvements. Ultimately, organizations that adopt an integrated approach-aligning clinical, operational, and commercial priorities-will be best positioned to deliver safe, timely, and cost-effective acute psychiatric care using injectable ziprasidone mesylate.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Ziprasidone Mesylate for Injection Market, by Indication

  • 8.1. Acute Agitation In Schizophrenia
    • 8.1.1. Moderate
    • 8.1.2. Severe
  • 8.2. Acute Manic Episodes In Bipolar Disorder
    • 8.2.1. Moderate
    • 8.2.2. Severe

9. Ziprasidone Mesylate for Injection Market, by Strength

  • 9.1. 20 Mg
  • 9.2. 40 Mg
  • 9.3. 60 Mg

10. Ziprasidone Mesylate for Injection Market, by Packaging

  • 10.1. Multi-Dose Vial
  • 10.2. Single-Dose Vial

11. Ziprasidone Mesylate for Injection Market, by Age Group

  • 11.1. Adult Patients
  • 11.2. Geriatric Patients

12. Ziprasidone Mesylate for Injection Market, by End User

  • 12.1. Hospital Pharmacy
    • 12.1.1. Emergency Department
    • 12.1.2. Psychiatric Ward
  • 12.2. Specialty Clinic
    • 12.2.1. Day Hospital
    • 12.2.2. Outpatient Clinic

13. Ziprasidone Mesylate for Injection Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Ziprasidone Mesylate for Injection Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Ziprasidone Mesylate for Injection Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Ziprasidone Mesylate for Injection Market

17. China Ziprasidone Mesylate for Injection Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Aurobindo Pharma Limited
  • 18.6. Cipla Limited
  • 18.7. Dr. Reddy's Laboratories Ltd.
  • 18.8. Glenmark Pharmaceuticals Ltd.
  • 18.9. Jubilant Generics Limited
  • 18.10. Lupin Limited
  • 18.11. Mylan N.V.
  • 18.12. Pfizer Inc.
  • 18.13. Sandoz International GmbH
  • 18.14. Sun Pharmaceutical Industries Ltd.
  • 18.15. Teva Pharmaceutical Industries Ltd.
  • 18.16. Torrent Pharmaceuticals Ltd.
  • 18.17. Zydus Cadila

LIST OF FIGURES

  • FIGURE 1. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY 20 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY 20 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY 20 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY 40 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY 40 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY 40 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY 60 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY 60 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY 60 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY MULTI-DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY MULTI-DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY MULTI-DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SINGLE-DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SINGLE-DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SINGLE-DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY GERIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY GERIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY EMERGENCY DEPARTMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY EMERGENCY DEPARTMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY EMERGENCY DEPARTMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PSYCHIATRIC WARD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PSYCHIATRIC WARD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PSYCHIATRIC WARD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY DAY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY DAY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY DAY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY OUTPATIENT CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY OUTPATIENT CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY OUTPATIENT CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 160. GCC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. GCC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 163. GCC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 164. GCC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 165. GCC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 166. GCC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GCC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. GCC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 169. GCC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 190. G7 ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. G7 ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. G7 ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 193. G7 ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 194. G7 ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 195. G7 ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 196. G7 ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. G7 ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. G7 ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 200. NATO ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. NATO ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 202. NATO ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 203. NATO ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 204. NATO ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 205. NATO ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 206. NATO ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. NATO ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. NATO ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 209. NATO ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)